Sarepta Therapeutics (SRPT) Active on Drisaparsen News
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $39.42 -0.45%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 4.8%
Revenue Growth %: +29.4%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 4.8%
Revenue Growth %: +29.4%
Join SI Premium – FREE
GlaxoSmithKline plc (NYSE: GSK) Drisaparsen will get FDA breakthrough therapy designation, the company said in an email obtained by Bloomberg.
Investors are watching shares of Sarepta Therapeutics, Inc. (Nasdaq: SRPT) in the wake of the news. Yesterday, Deutsche Bank said Eteplirsen breakthrough designation may be at risk when Drisapersen comes to market, though Eteplirsen may have substantial safety advantages which could help it retain the designation.
Investors are watching shares of Sarepta Therapeutics, Inc. (Nasdaq: SRPT) in the wake of the news. Yesterday, Deutsche Bank said Eteplirsen breakthrough designation may be at risk when Drisapersen comes to market, though Eteplirsen may have substantial safety advantages which could help it retain the designation.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- CSX Corp. (CSX) Shares Trade Lower Ahead of Results, Down 2.2%
- Amazon (AMZN) Earlier Said To Receive Comment at Channel Check Firm
Create E-mail Alert Related Categories
Trader TalkRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
